Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates - Lee, CH; Voss, MH; Carlo, MI (J Clin Oncol, 2022)
et al.